Cases of Powassan virus disease, a rare but serious tick-borne illness, have increased markedly in the United States in recent years, raising public health concerns. The virus, transmitted primarily by deer ticks, can cause severe neurological symptoms and has been documented most frequently in the Northeast and Upper Midwest regions.

Powassan virus was first identified in 1958 in Powassan, Ontario, and has since been recognized as a dangerous pathogen due to its ability to invade the central nervous system, leading to encephalitis or meningitis. These conditions involve inflammation of the brain or the tissues surrounding it, respectively. Symptoms can include memory loss, difficulty speaking, seizures, and other neurological impairments.

While infection with Powassan virus remains rare, the number of reported cases has risen sharply from seven in 2015 to 76 in 2025, according to data from the Centers for Disease Control and Prevention (CDC). Experts attribute this increase in part to climate change, which has led to longer periods of warm, humid weather favorable for ticks. The extended tick season allows for more human exposure, while milder winters have contributed to larger populations of tick hosts, such as rodents and deer. This ecological shift potentially expands the geographic range of infected ticks.

Transmission of Powassan virus is notably rapid compared to Lyme disease. Whereas Lyme requires a tick to remain attached for 16 to 24 hours to transmit bacteria, Powassan virus can be passed within about 15 minutes of a tick bite. The severity of illness typically depends on the amount of virus transmitted during feeding.

Many individuals infected with Powassan virus experience few or no symptoms. Those presenting symptoms initially may develop fever and flu-like signs including muscle aches and fatigue. However, in a subset of cases, the virus reaches the nervous system within weeks, causing neurological symptoms such as confusion, speech difficulties, loss of coordination, paralysis, or seizures. Fatality rates among symptomatic patients can reach 15 percent, with approximately half of survivors suffering long-term neurological effects, including memory problems, speech difficulties, and impaired mobility.

There is currently no specific treatment or vaccine for Powassan virus infection. Care for severe cases involves supportive measures such as intravenous fluids and, if necessary, respiratory or feeding support. Steroids may be used to reduce brain inflammation, and rehabilitation therapies can aid recovery in patients with persistent neurological deficits.

To reduce the risk of infection, public health officials recommend protective measures to avoid tick bites. These include wearing long pants tucked into socks, using insect repellents registered by the Environmental Protection Agency, and donning clothing treated with permethrin. Prompt removal of ticks with fine-tipped tweezers, followed by vigilant monitoring for symptoms in the ensuing month, is essential. Experts emphasize the importance of awareness, given that Powassan virus infections may be underdiagnosed due to symptom overlap with other illnesses and unrecognized tick exposures.

As tick populations and associated diseases continue to expand, health specialists urge the public and clinicians to remain attentive to the risks posed by Powassan virus and other tick-borne pathogens, despite their relative rarity. The increasing case counts underscore the need for ongoing surveillance and preventive strategies to mitigate the virus’s impact on human health.